BDBM221626 US9303045, 119::US9695195, 148

SMILES CN1C2COCC1CC(C2)NC(=O)c1cn(-c2cncs2)c2ccccc12

InChI Key InChIKey=ROQQDFDIRFHQTE-UHFFFAOYSA-N

Data  3 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 3 hits for monomerid = 221626   

Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM221626(US9303045, 119 | US9695195, 148)
Affinity DataIC50:  0.400nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM221626(US9303045, 119 | US9695195, 148)
Affinity DataIC50:  0.400nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM221626(US9303045, 119 | US9695195, 148)
Affinity DataIC50:  0.400nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent